All In Biotech

Drug Trial Radar · NCT07511218

A Phase I Clinical Study of AHB - 171 in Healthy Participants(HP) and Chronic Hepatitis B (CHB) Participants

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AHB - 171 Injection in Healthy Participants (HP) and Chronic Hepatitis B(CHB) Participants

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Apr 13, 2026

Primary completion

Dec 30, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Ausper Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability, immunogenicity and Pharmacokinetics (PK) characteristics of AHB-171 Injection in healthy participants (Part A) and participants with chronic hepatitis B (CHB, Part B), and assess its preliminary efficacy in CHB participants.

Conditions

  • Chronic Hepatitis B Infection

Interventions

  • AHB-171 InjectionDrug

    AHB-171 Injection is adminstrated via subcutaneous injection

  • PlaceboDrug

    Placebo is admistrated via subcutaneous injection

  • Nucleos(t)ide Analogue (NA)Drug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A & Part B Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
  2. Severity of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
  3. Change from baseline in laboratory testsTime frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
  4. Change from baseline in physical examinationsTime frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
  5. Change from baseline in vital signsTime frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
  6. Change from baseline in electrocardiograms (ECGs)Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
  7. Part A:Plasma Cmax of AHB-171Time frame: Up to Day 8
  8. Part A:Plasma Tmax of AHB-171Time frame: Up to Day 8
  9. Part A Plasma AUC of AHB-171Time frame: Up to Day 8
  10. Part A Plasma t1/2 of AHB-171Time frame: Up to Day 8
  11. Proportion of participants with clinically significant abnormalities in laboratory testsTime frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
  12. Proportion of participants with clinically significant abnormalities in electrocardiograms (ECGs)Time frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
  13. Proportion of participants with physical examinationsTime frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks
  14. Proportion of participants with other vital signsTime frame: PartA:Up to 16 weeks, PartB: Up to 48 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • AusperBio Investigational Site

    Ch’ang-ch’un, Jilin, China · Recruiting

  • AusperBio Investigational Site

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.